🇺🇸 FDA
Patent

US 10071083

Use of gaboxadol in the treatment of tinnitus

granted A61KA61K2300/00A61K31/437

Quick answer

US patent 10071083 (Use of gaboxadol in the treatment of tinnitus) held by OVID THERAPEUTICS INC. expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2300/00, A61K31/437, A61K31/5513, A61P